Rivaroxaban, marketed as Xarelto in the United States, is a direct factor Xa inhibitor, which is a class of anticoagulant drugs. The first available orally active blood thinner, Xarelto is also the only anticoagulant that is prescribed in a uniform dose, rather than in specific doses. Furthermore, patients are not required to first undergo a blood test,unlike alternative blood thinners, such as Warfarin. First approved by the Food and Drug Administration (FDA) for patients who had recently undergone knee or hip replacement surgery, Xarelto was later approved via a fast-track regulatory review for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).
One of the most severe side effects associated with Xarelto is uncontrollable bleeding. Anticoagulants work by prohibiting blood clots from forming, ensuring the flow of blood to vital organs. The danger is that if any physical injuries are sustained, the medication will impede the natural clotting of blood that protects against hemorrhaging. In the case of Xarelto, there is no known antidote to counteract the bleeding, which makes this side effect especially dangerous and potentially fatal.
If you are currently taking Xarelto, it is highly recommended that you make sure to avoid any activities associated with significant risks of bruising, blunt trauma, and other physical injuries. If you do sustain an injury while taking Xarelto, it is vital that you immediately contact your doctor.
Side effects may include the following:
- Intestinal or abdominal bleeding
- Rectal bleeding
- Nose bleeds
- Low blood pressure
- Muscle pain
- Heart attack
Current lawsuits filed regarding Xarelto allege that the drug causes patients to experience uncontrollable and irreversible intracranial or intestinal bleeding. These side effects can be fatal because, unlike previous versions of blood thinners whose negative effects could be reversed, there is currently no effective reversal agent doctors can use to stop the bleeding. Further, Xarelto’s labeling failed to adequately convey to doctors and patients this increased risk of bleeding. Currently, the majority of pending lawsuits have been consolidated into a single multidistrict litigation (MDL No. 2592) in the Eastern District of Louisiana to help conserve resources and process the cases more efficiently. As more studies have shown Xarelto’s tendency to cause uncontrollable bleeding, the number of lawsuits against Bayer and J&J have increased dramatically to nearly 3,600 cases as of November 2015 and another 400 cases in a Philadelphia mass tort. The MDL, along with a separate mass tort action inPennsylvania, is still accepting more lawsuits from patients experiencing Xarelto’s harmful effects.
The makers of Xarelto had a duty to more thoroughly test their product and provide sufficient safety warnings about all potential side effects. While defective drug litigation can be challenging and complex, the attorneys at Pope McGlamry have the experience and expertise to ensure you receive the compensation to which you are entitled. For a confidential case evaluation, please call (Atlanta-877-285-7656 or Columbus-877-265-7656) or contact us online.